At A Glance
M3 MI's MARS Consumer Health Study empowers healthcare advertisers to create personalized campaigns by offering nuanced audience insights. By layering behavioral and engagement attributes, MARS enables accurate targeting, driving stronger engagement, improved ad recall, and measurable campaign outcomes across connected TV (CTV), social, and display channels.In our Ask the Expert Series, we interview leaders from our partner organizations who are helping lead their brands to new heights in AdTech. Today’s interview is with Dan Lynch a Senior Manager, Insights and Analysis at M3 MI, the company behind the MARS Consumer Health Study and MARS Audiences.
Audience impact across health vertical
Which healthcare advertisers see the greatest impact from MARS audiences? Could you share an example of how health marketers have successfully utilized your data to achieve specific campaign goals, such as patient engagement, awareness, or adherence?
We’re seeing a clear shift in healthcare advertising away from generic, one-size-fits-all campaigns. With MARS, advertisers from pharmaceuticals, over-the-counter (OTC), health insurance companies, and hospitals are seeing the greatest impact by defining highly specific patient and caregiver personas and using those insights to build personalized media plans and deliver unique messaging by segment. As a result, our partners are seeing stronger engagement, increased ad recall, and more effective outcomes because they’re speaking directly to what matters most to each audience.
Media agencies who utilize the MARS Consumer Health Study to build their strategic marketing plans are seeing a great impact by then taking those strategic targets and activating them. Those who are not activating those audiences are really missing out on bringing their strategy to consumer screens.
Building stronger health campaigns with advanced segmentation
What key health-related audience segments does MARS offer?
While other competitors may offer caregiver segments by condition, we go further by layering engagement levels, such as caregivers actively involved in medical decisions or those who regularly discuss care with physicians. Similarly, for patients, we don’t stop at identifying over 60 health conditions; we add behavioral dimensions like whether they’re proactive in managing their health or primarily doctor-led. These nuanced attributes allow advertisers to craft personalized campaigns that resonate on a much deeper level. We can also look at patients that are willing to pay more for an Rx not covered by their insurance, which has been a trend with GLP-1s.
How can health advertisers use these segments to craft more personalized and effective campaigns?
Advertisers can use MARS’ advanced segmentation to move beyond simple demographics or condition-based targeting by layering behavioral and engagement attributes for greater relevance and impact. With MARS, a single condition can be the starting point for building multiple test-and-learn audiences to identify prime prospects. For example, GLP-1 patients have diverse treatment journeys; some pay out-of-pocket due to lack of insurance coverage, others switch brands for cost savings, and some purchase directly through patient websites. Each of these scenarios represents a distinct audience that can be created using MARS data, enabling highly personalized activation strategies.
Data sourcing and quality
How does MARS source and curate consumer data relevant to health audiences?
Our audiences are survey-based, first-party data built from the MARS Consumer Health Study and Kantar’s trusted LifePoints Panel. We do not use medical claims, insurance data, or personal health records; our data is 100% self-reported. The study has over 5,000 different healthcare data points used to create syndicated and custom audiences. Our syndicated audiences are curated based on marketplace trends (e.g., we’ve added more information on GLP-1s), client feedback for enhancements to the MARS study, and reaching audiences medical claims data cannot (e.g., caregivers, treatment satisfaction, act based on healthcare advertising).
What data quality standards do you follow, and how do you ensure consistency and reliability, especially for sensitive or regulated health-related data?
M3 MI is part of M3 Global Research which is committed to transparency and high-quality data with ISO (International Organization for Standardization) certifications. These certifications demonstrate that our research practices align with international regulations.
In a crowded data marketplace, what unique attributes set MARS apart, particularly for health advertisers?
We don’t just identify patients or caregivers, we uncover their motivations, preferences, and behaviors, enabling advertisers to build highly targeted and meaningful audiences that competitors simply can’t replicate.
The MARS Consumer Health Study offers an extensive range of data for audience building, spanning healthy living profiles, OTC, vitamins, and prescription purchasing behaviors, as well as media consumption habits and lifestyle activities.
How MARS ensures regulatory compliance
What measures does MARS take to maintain data privacy and regulatory compliance?
We take a privacy-first approach to exceed all Network Advertising Initiative (NAI), Health Insurance Portability and Accountability Act (HIPAA), and California Consumer Privacy Act (CCPA) regulations. Since the data to build our audiences is self-reported via the MARS Consumer Health Study, we do not use PII data. We also take the following steps to maintain data privacy and compliance:
- State regulatory compliance: We proactively exclude survey respondents for audience seeds from certain states with consumer privacy laws that preclude audience data use
- Consent and transparency: Survey panelists are required to double-opt-in to all data usage terms before participating in the MARS study. Our panel partner’s privacy policy clearly explains use cases such as look-alike modeling and audience creation.
- Privacy-safe modeling: Data is scaled using propensity models built from an offline, people-based national consumer database. All seed survey data is removed from final models to eliminate any risk of re-identification, ensuring respondents are never targeted directly based on their survey responses.
Click here for full details on M3 MI’s privacy policy
How do these efforts help advertisers navigate an evolving regulatory landscape while ensuring ethical standards?
By relying solely on double opt-in, self-reported data, and removing identifiers, we guarantee that our approach is 100% privacy-safe and compliant. This gives advertisers confidence that our audiences are built on ethical, transparent practices without compromising consumer trust.
Success stories
Could you share a recent success story where a health advertiser achieved significant campaign improvements using M3 MI’s MARS data? What were the key factors behind that success, such as ROI, engagement lift, or conversion rates?
One recent success story involved a diabetes medical device advertiser trying to breakthrough in a cluttered marketing landscape. Their initial broad, non-personalized media campaign delivered lower than expected digital engagement. To address this, the company conducted segmentation research and identified three distinct patient personas. However, the research lacked actionable media insights and a way to effectively reach these personas in the digital world.
That’s where MARS data came in. Using the MARS Consumer Health Study, M3 MI mapped the existing personas to uncover each group’s unique media habits. These insights enabled the media agency to design tailored strategies for each persona. Additionally, M3 MI built custom, propensity-modeled persona audiences for activation across CTV, social, and display channels, ensuring precise targeting and personalized messaging. This strategic shift to personalized persona marketing transformed the campaign from a one-size-fits-all approach to a patient-first model. The company saw a significant lift in website engagement and a measurable increase in ROI.
Resources to maximize your campaigns
Where can readers find additional resources, case studies, or insights to learn more about MARS audience solutions?
Interested healthcare marketers can explore additional resources by visiting our Audience Solutions page. There, they’ll find a comprehensive overview, a detailed taxonomy of syndicated audiences, and other helpful materials. For personalized support or further information on customized audiences, they can also reach us directly at info@M3-MI.com.
Contact us
About our expert
Dan Lynch
Senior Manager, Insights and Analysis, M3 MI
Dan Lynch is a seasoned leader in strategic marketing insights and activation with over 20 years at healthcare focused media agencies. At M3 MI, he helps pharmaceutical companies, media partners, and agencies leverage our syndicated research to address critical business needs. Dan is also a lead of the MARS addressable audience initiative, applying his expertise in developing unique audience personas from our data and activating them across programmatic channels.
About M3 MI
M3 MI, a division of M3 USA, is the leading provider of unbiased syndicated research for the healthcare industry. We specialize in media measurement, advertising intelligence, and audience insights and activation. Leveraging robust datasets, rigorous methodologies, and decades of healthcare expertise, M3 MI delivers a deeper understanding of patients, caregivers, and healthcare professionals, their behaviors, attitudes, media habits, and communication preferences. These insights empower marketers to make informed, data-driven decisions.
Latest posts
Are Traasdahl, CEO and founder of Tapad, the leader in cross-device marketing technology and now a part of Experian, has been named Founder of the Year by the Global Startup Awards. The Global Startup Awards' Founder of the Year Award recognizes an individual that has pushed the boundaries of technology to empower new innovations and ideas. The Global Startup Awards places each year's regional category winners against each other to determine whose achievements stand out from the rest of the startup ecosystem through nomination, voting and jury evaluation. In May 2016, the Nordic Startup Awards named Traasdahl Founder of the Year. "Are is a force of nature and his creativity and passion know no boundaries, it seems," said George Tilesch, Global Startup Awards juror and U.S. managing partner of Innomine Group. "Extra kudos for the mentoring work and the Norwegian superfund plans. Are knows giving back is of the utmost importance." "Are is a superstar within the Norwegian startup ecosystem," said Kim Balle, founding partner and CEO of the Global Startup Awards. "From the jury feedback I could see that not only are his impressive achievements the reason for their rating, but also his focus and ability to give back to the startup scene played an important factor in him winning the category." "It is an enormous honor to be named Founder of the Year by the Global Startup Awards," said Traasdahl. "I am so committed to fostering entrepreneurship both at Tapad and throughout the startup space. This win is a remarkable bookend for a stellar year that began with our acquisition by the Telenor Group and continued with best-in-class product innovation, superior solutions for our clients and our Propeller Program that is so dear to my heart." Tapad's Propeller Program hosts five early-stage companies at Tapad's New York headquarters for one year to mentor them through global expansion. The participants of this inaugural program come from Traasdahl's native Norway. For more information on the Global Startup Awards, please visit: http://www.globalstartupawards.com/#gsa. Contact us today
NEW YORK, Nov. 29, 2016 /PRNewswire/ — For the second consecutive year, Tapad, part of Experian, has been listed among Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. Tapad, number 147 on the 2016 Deloitte list, is the leading provider of unified, cross-device marketing technology solutions. "It is an honor to once again be recognized by Deloitte for our growth and momentum, particularly given the stature of the other technology companies on the list," said Are Traasdahl, founder and CEO of Tapad. "Our product innovation, particularly in TV analytics and measurement, is a major contributor to our progress. I'm extremely proud of our hard-working, talented team for continually executing at such a high level." "Today, when every organization can be a tech company, the most effective businesses not only foster the courage to explore change, but also encourage creativity in using and applying existing assets in new ways, as resourcefully as possible," said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications industry leader. "This ingenious approach to innovation calls for the encouragement of curiosity and collaboration both within and outside the office walls." "This year's Fast 500 winners showcase that when organizations are open to diverse perspectives and insights, they are able to create an environment for their employees and customers to see the possibilities and ingenious solutions that might lie ahead," added Jim Atwell, national managing partner of the emerging growth company practice, Deloitte & Touche LLP. "Entrepreneurial environments foster change and innovation within businesses, and we look forward to watching these companies continue to drive change across all sectors." Contact us today
Distribution via LiveRamp enables seamless cross-device customer experiences through more platforms NEW YORK, Nov. 15, 2016 /PRNewswire/ – Tapad, now part of Experian and the leading provider of unified cross-device marketing technology solutions, today announced an expanded partnership with LiveRamp™, an Acxiom® company and leading provider of omnichannel identity resolution, to make the proprietary Tapad Device Graph™ accessible beyond Tapad-hosted direct integrations. Through LiveRamp, Tapad's Device Graph Access now extends to more than 400 ad tech and mar tech platforms. Tapad's Device Graph™ enables marketers to understand, monetize and measure consumer engagement across all digital channels, and Tapad's unified consumer view is recognized as one of the most accurate, scalable cross-device solutions in the market today. Through the expanded partnership with LiveRamp, the Tapad Device Graph can be distributed to the hundreds of platforms used to reach consumers on digital channels and measure campaign performance – even as devices are added daily to Tapad's extensive graph. "Increasingly, marketers want access to cross-device targeting and measurement capabilities within their preferred platforms," said Anneka Gupta, chief product officer of LiveRamp. "Our expanded partnership makes it easy for marketers to access Tapad's graph through the rapidly growing set of integrations available in our partner ecosystem." This is the latest of several initiatives between the two technology platforms designed to make the integration of cross-screen platforms seamless, privacy-safe and easy to use for dynamic and engaging marketing efforts. "During the past year, Tapad has expanded its global presence and rapidly grown its data business – Tapad Coral – doubling the number of companies integrating our device graph into their platforms and growing our annualized run rate by 210%," said Pierre Martensson, GM of Tapad Coral and APAC. "Our expanded partnership with LiveRamp positions us to meet the increased demand for Tapad Device Graph Access and enable new platforms to apply our graph with unprecedented speed." Contact us today